Annual Cash & Cash Equivalents
$56.86 M
-$10.35 M-15.40%
31 December 2023
Summary:
ProShares UltraPro Short Nasdaq Biotechnology annual cash & cash equivalents is currently $56.86 million, with the most recent change of -$10.35 million (-15.40%) on 31 December 2023. ZBIO annual cash & cash equivalents is now -15.40% below its all-time high of $67.21 million, reached on 31 December 2022.ZBIO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$360.04 M
+$176.11 M+95.75%
30 September 2024
Summary:
ProShares UltraPro Short Nasdaq Biotechnology quarterly cash and cash equivalents is currently $360.04 million, with the most recent change of +$176.11 million (+95.75%) on 30 September 2024. Over the past year, it has increased by +$287.73 million (+397.90%). ZBIO quarterly cash and cash equivalents is now at all-time high.ZBIO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZBIO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -15.4% | +397.9% |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
ZBIO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -15.4% | at low | at high | +869.0% |
| 5 y | 5 years | -15.4% | at low | at high | +869.0% |
| alltime | all time | -15.4% | at low | at high | +869.0% |
ProShares UltraPro Short Nasdaq Biotechnology Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $360.04 M(+95.7%) |
| June 2024 | - | $183.93 M(+395.0%) |
| Mar 2024 | - | $37.15 M(-34.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2023 | $56.86 M(-15.4%) | $56.86 M(-21.4%) |
| Sept 2023 | - | $72.31 M |
| Dec 2022 | $67.21 M | - |
FAQ
- What is ProShares UltraPro Short Nasdaq Biotechnology annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ProShares UltraPro Short Nasdaq Biotechnology?
- What is ProShares UltraPro Short Nasdaq Biotechnology annual cash & cash equivalents year-on-year change?
- What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ProShares UltraPro Short Nasdaq Biotechnology?
- What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash and cash equivalents year-on-year change?
What is ProShares UltraPro Short Nasdaq Biotechnology annual cash & cash equivalents?
The current annual cash & cash equivalents of ZBIO is $56.86 M
What is the all time high annual cash & cash equivalents for ProShares UltraPro Short Nasdaq Biotechnology?
ProShares UltraPro Short Nasdaq Biotechnology all-time high annual cash & cash equivalents is $67.21 M
What is ProShares UltraPro Short Nasdaq Biotechnology annual cash & cash equivalents year-on-year change?
Over the past year, ZBIO annual cash & cash equivalents has changed by -$10.35 M (-15.40%)
What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ZBIO is $360.04 M
What is the all time high quarterly cash and cash equivalents for ProShares UltraPro Short Nasdaq Biotechnology?
ProShares UltraPro Short Nasdaq Biotechnology all-time high quarterly cash and cash equivalents is $360.04 M
What is ProShares UltraPro Short Nasdaq Biotechnology quarterly cash and cash equivalents year-on-year change?
Over the past year, ZBIO quarterly cash and cash equivalents has changed by +$287.73 M (+397.90%)